Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12607000552482
Ethics application status
Approved
Date submitted
12/10/2007
Date registered
26/10/2007
Date last updated
29/06/2012
Type of registration
Retrospectively registered

Titles & IDs
Public title
A Phase 1 randomised, double blinded within dose, controlled, dose- escalation, safety and immunogenicity study of a blood-stage vaccine (MSP2-C1/ISA 720) against Plasmodium falciparum MSP2 in healthy volunteers
Scientific title
Safety and tolerability trial of a randomised, placebo-controlled MSP2-C1/ISA720 malaria vaccine in healthy volunteers
Universal Trial Number (UTN)
Trial acronym
QP07C08
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria 2446 0
Condition category
Condition code
Infection 2550 2550 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The MSP2-C1/ ISA720 malaria vaccine is supplied as a milky white emulsion in single dose vials. Each 5 mL vial contains 0.8 mL, of which 0.5 mL is the intended volume to be injected. 0.5 mL of vaccine contains the equivalent of 0.15 ml of buffer containing antigen emulsified in Montanide® ISA720. The MSP2-C1/ ISA720 vaccine and ISA720 Control conforms to established requirements for sterility, safety and identity. The MSP2-C1/ISA720 malaria vaccine will be injected intramascularly into the 3 subgroups of participants within the intervention group. The vaccine will be provided in multiple doses, as three immunizations, twelve weeks apart. The first subgroup will receive 10 micrograms in each injection, the second subgroup will receive 40 micrograms in each injection, and the third subgroup will receive 80 micrograms in each injection.
Intervention code [1] 2176 0
Prevention
Comparator / control treatment
Buffered ISA 720 adjuvant is the "placebo" and this is given in three doses, 12 weeks apart, in 0.5 ml volume, intramuscularly into the 3 subgroups of participants in the control group. The first subgroup will receive 10 micrograms in each injection, the second subgroup will receive 40 micrograms in each injection, and the third subgroup will receive 80 micrograms in each injection.
Control group
Placebo

Outcomes
Primary outcome [1] 3456 0
Safety and tolerability
Timepoint [1] 3456 0
Safety and tolerability of 3 vaccinations assessed from baseline by diary cards, telephone calls at days 0, 1, 21, 85, 105, 169 and 189 and by clinical evaluations at days 3,7,14,28,56,84,87,91,98,112,140, 168, 171, 175, 182, 196 and 336
Secondary outcome [1] 5760 0
Humoral and cellular immune
Timepoint [1] 5760 0
Humoral and cellular immune response assessed by blood analysis at baseline out to days 0, 28, 84, 112, 168, 196 and 336

Eligibility
Key inclusion criteria
Healthy, withhold donating blood.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Malaria disease or exposure, intercurrent disease, recent illness, treatment with corticosteroids, anti-coagulant, anti-inflammatory or immunomodulator drugs, history severe allergic reaction or anaphylaxis, live vaccination within 4 weeks or dead vaccination within 2 weeks or participation in a clinical trial in the 4 weeks prior

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Eligible patients assigned to cohorts and randomised and blinded within cohorts.
Blinded treatment provided by identical and blinded syringes prepared by unblinded pharmacist according to randomisation schedule provided by study statistician. The statistician is off-site.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation schedule provided by study statistician. Randomisation is based on a permuted block process, with the random numbers being generated by an application of the "Mersenne-Twister" algorithm from Matsumoto and Nishimura (1998). It involves a twisted General Functional System Requirement (GFSR) with period /2^19937 - 1/ and equidistribution in 623 consecutive dimensions (over the whole period). The "seed" is a 624-dimensional set of 32-bit integers plus a current position in that set.

Reference: Matsumoto, M. and Nishimura, T. (1998) Mersenne Twister: A 623-dimensionally equidistributed uniform pseudo-random number generator, Association for Computing Machinery (ACM) Transactions on Modeling and Computer Simulation, 8, 3–30.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Dose-escalating
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
15/10/2007
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
45
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment postcode(s) [1] 275 0
4006

Funding & Sponsors
Funding source category [1] 2696 0
Other Collaborative groups
Name [1] 2696 0
The PATH Malaria Vaccine Initiative
Country [1] 2696 0
United States of America
Primary sponsor type
Other
Name
The Queensland Institute of Medical Research
Address
300 Herston Rd, Herston, Queensland, 4006
Country
Australia
Secondary sponsor category [1] 2441 0
Other Collaborative groups
Name [1] 2441 0
The PATH Malaria Vaccine Initiative
Address [1] 2441 0
7500 Old Georgetown Rd, 12th Floor, Bethesda, MD, 20814 - 6133
Country [1] 2441 0
United States of America

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 4618 0
The Queensland Institute of Medical Research Human Research Ethics Committee
Ethics committee address [1] 4618 0
Ethics committee country [1] 4618 0
Australia
Date submitted for ethics approval [1] 4618 0
Approval date [1] 4618 0
10/10/2007
Ethics approval number [1] 4618 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 28108 0
Address 28108 0
Country 28108 0
Phone 28108 0
Fax 28108 0
Email 28108 0
Contact person for public queries
Name 11265 0
Dr Suzanne Elliott
Address 11265 0
Q-Pharm Pty Ltd
QIMR
Clive Berghofer Cancer Research Centre
Level D
300 Herston Rd
Herston QLD 4006
Country 11265 0
Australia
Phone 11265 0
61 7 3845 3636
Fax 11265 0
61 7 3845 3637
Email 11265 0
[email protected]
Contact person for scientific queries
Name 2193 0
Dr Suzanne Elliott
Address 2193 0
Q-Pharm Pty Ltd
QIMR
Clive Berghofer Cancer Research Centre
Level D
300 Herston Rd
Herston QLD 4006
Country 2193 0
Australia
Phone 2193 0
61 7 3845 3636
Fax 2193 0
61 7 3845 3637
Email 2193 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIBlood stage vaccines for Plasmodium falciparum2010https://doi.org/10.4161/hv.6.8.11446
EmbaseHuman Immunization with a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains.2018https://dx.doi.org/10.1093/infdis/jiy170
N.B. These documents automatically identified may not have been verified by the study sponsor.